KMDA - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים Kamada Pharma

Is it worth investing in Kamada Ltd. (KMDA), a leader in developing targeted proteins to combat orphan lung pathologies? The rolling 12-month sales growth rate year-over-year provides the answer, where the current parameter equals 12.60. Kamada Ltd. (KMDA) revenues rely on the production of plasma-derived medicines and a partnership with Takeda. An impeccable global image and government contracts confirm the high quality of the brand's products.
kamada.com (KMDA) - פילוחי מדדים ודוחות פיננסיים

This indicator measures revenue dynamics over the last twelve months, determining the business's capacity for organic scaling while filtering out market noise. By analyzing the YoY sales growth trajectory over a rolling period, an investor assesses the sustainability of the fundamental trend for Kamada Ltd. (KMDA), where steady growth confirms the efficiency of costly, specialized cold-chain logistics for the delivery of critical plasma-derived therapies.